Lithium Aspartate Therapy Ineffective for Post–COVID-19 Condition Fatigue, Brain Fog

News
Article

Additional research is needed to determine if the therapy can help with cognitive symptoms of post–COVID-19 condition.

For patients with neurologic post–COVID-19 condition (PCC), lithium aspartate therapy was not effective at reducing symptoms of fatigue and cognitive dysfunction, according to a new study published in JAMA Network Open.1

The study did, however, indicate that a higher dose of lithium aspartate may be effective in reducing cognitive symptoms, but another trial is needed to confirm the results.

For patients with PCC, symptoms of COVID-19 persist at least 4 weeks after recovering from the initial infection. There are currently no approved treatments for neurologic PCC. Due to lithium’s neuroprotective qualities, the researchers hypothesized that it could be a potential treatment for neurologic PCC.

Neurologic symptoms of post–COVID-19 condition did not experience symptom improvement with lithium aspartate therapy. | image credit: freshidea - stock.adobe.com

Neurologic symptoms of post–COVID-19 condition did not experience symptom improvement with lithium aspartate therapy. | image credit: freshidea - stock.adobe.com

The researchers performed a randomized, double-blind, placebo-controlled trial with 3 weeks of follow-up; all participants were then enrolled in an open-label lithium dose-finding study with 6 weeks of follow-up. Participants included those who reported fatigue or cognitive dysfunction that persisted more than 4 weeks after testing positive for COVID-19. Other inclusion criteria were a Fatigue Severity Scale-7 (FSS-7) or Brain Fog Severity Scale (BFSS) score of 28 or more, a Beck Depression Inventory-II score of less than 24, and no history of other conditions that could cause fatigue or cognitive dysfunction. Overall, 52 participants were enrolled (30 men, 22 women; mean age, 58.54 years). The primary outcome was the change in sum of FSS-7 and BFSS scores.

In the initial trial, participants were randomly assigned 1:1 to receive lithium aspartate (10 mg to 15 mg per day) or placebo for 3 weeks followed by open-label lithium aspartate (10 mg to 15 mg per day) for 2 weeks. Two participants who had been assigned to lithium therapy were lost to follow-up. Participants took 2 capsules (5 mg each) of lithium for the first 10 days; if their symptoms persisted, they could take 3 capsules each for the last 11 days.

READ MORE: FDA Authorizes IND For Phase 2 Clinical Trial Evaluating Treatment for Post–COVID-19 Condition

The results showed no significant differences in the primary outcome scores between the treatment and placebo groups (-3.6; 95% CI, -16.6 to 9.5). The researchers did not observe any significant differences in the secondary outcomes between the two groups, including Insomnia Severity Scale, Generalized Anxiety Scale-2, Short Form-12 Health Survey (physical and mental), Well-Being Scale, Headache and Body Pain Bother Scale, Digit Symbol Substitution, and Delayed Recall Tests from the Montreal Cognitive Assessment.

In the dose-finding study, the researchers invited 43 participants—excluding those who responded to the placebo—to take open-label lithium aspartate doses of up to 45 mg per day for 6 weeks. Participants initially took 2 5 mg capsules of lithium aspartate twice daily for 7 days before increasing to a maximum dosage of 45 mg a day. Follow-up occurred 3 weeks after each participant achieved the maximum dosage.

Of the 5 participants in the dose-finding study, 3 saw significantly greater reductions in fatigue and cognitive dysfunction compared with the 15 mg per day dose. Even among these participants, the researchers observed a more significant reduction in symptoms among the participants who had serum lithium levels of 0.18 and 0.49 mEq/L compared with 0.10 mEq/L.

The researchers note that the dose-finding study is limited by its size and selection bias. However, future studies that target serum lithium levels of 0.18 to 0.50 mEq/L are warranted to address the dearth of evidence-based treatments for the large number of patients with neurologic PCC.

READ MORE: COVID-19 Resource Center

Reference
1.Guttuso, T Jr, Zhu J, Wilding G. Lithium aspartate for long COVID fatigue and cognitive dysfunction: a randomized clinical trial. JAMA Netw Open. 2024;7(10):e2436874. doi:10.1001/jamanetworkopen.2024.36874

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
Image Credit: tirachard | stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.